Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures;
Age ≥ 18 years
Pathologically confirmed mature T-cell and NK-cell lymphomas.
Using the Lugano 2014 criteria, the patient must have at least one measurable or evaluable lesion
Participants must have experienced disease progression, treatment failure, or intolerance following standard therapy. Patients with ALCL are required to have previously received anti-CD30-targeted therapy, while patients with NKTCL must have previously been treated with pegaspargase or L-asparaginase.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Adequate organ and bone marrow function
You may not be if
Lymphoma involvement in the central nervous system or meninges
Active infections
Prior treatment with an EZH2 inhibitor or an EZH1/2 dual inhibitor that was discontinued due to intolerance to toxicity;
For patients enrolled in Cohort 1, prior treatment with a JAK inhibitor that was discontinued due to intolerance to toxicity;
For patients enrolled in Cohort 2, prior treatment with an HDAC inhibitor that was discontinued due to intolerance to toxicity.
History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
Patients with mental disorders or those unable to provide informed consent
Any other condition deemed by the investigator to be unsuitable for study enrollment;
Pregnant or breastfeeding women, and subjects of childbearing potential who are unwilling to use contraception;
Individuals with a known hypersensitivity to any of the investigational drugs.
